Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2019--
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
company, announced today that management will present a company overview
at the Bank of America Merrill Lynch Health Care Conference 2019 on
Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel
in Las Vegas, Nevada.
A live audio webcast of the presentation will be available on the
Investors section of the Company’s website, www.alnylam.com.
A replay will be available on the Alnylam website within 48 hours after
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class of
innovative medicines with the potential to transform the lives of people
afflicted with rare genetic, cardio-metabolic, hepatic infectious, and
central nervous system/ocular diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically validated
approach for the treatment of diseases with high unmet need. ONPATTRO®
(patisiran) is the first-ever RNAi therapeutic approved by the U.S. FDA
for the treatment of the polyneuropathy of hereditary
transthyretin-mediated (hATTR) amyloidosis in adults and by the EMA for
the treatment of hATTR amyloidosis in adults with stage 1 or stage 2
polyneuropathy. Alnylam has a deep pipeline of investigational
medicines, including six product candidates in Phase 3 studies. Looking
forward, Alnylam will continue to execute on its “Alnylam 2020”
strategy of building a multi-product, commercial-stage biopharmaceutical
company with a sustainable pipeline of RNAi-based medicines to address
the needs of patients who have limited or inadequate treatment options.
Headquartered in Cambridge, MA, Alnylam employs over 1,000 people
worldwide. For more information, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190509005130/en/
Source: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom